Press Releases

Date Title and Summary Additional Formats
Toggle Summary AMICUS THERAPEUTICS COMMENCES PHASE 1 CLINICAL TRIALS FOR AT2220 FOR POMPE DISEASE
AMICUS THERAPEUTICS COMMENCES PHASE 1 CLINICAL TRIALS FOR AT2220 FOR POMPE DISEASE Cranbury, NJ, DECEMBER 14, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today
View HTML
Toggle Summary AMICUS THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER
AMICUS THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER Cranbury, NJ, October 2, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the
View HTML
Toggle Summary STUDIES PUBLISHED IN PNAS ON THE MECHANISM OF AMICUS' EXPERIMENTAL TREATMENT FOR GAUCHER DISEASE
STUDIES PUBLISHED IN PNAS ON THE MECHANISM OF AMICUS' EXPERIMENTAL TREATMENT FOR GAUCHER DISEASE Cranbury, NJ, September 20, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human
View HTML
Toggle Summary AMICUS THERAPEUTICS RAISES $60 MILLION SERIES D FINANCING
Company Also Makes Two Key Executive Appointments
View HTML
Toggle Summary AMICUS THERAPEUTICS ADDS GLENN P. SBLENDORIO TO BOARD OF DIRECTORS
Company Makes Executive and Management Appointments
View HTML
Toggle Summary AMICUS THERAPEUTICS FILES FOR INITIAL PUBLIC OFFERING
AMICUS THERAPEUTICS FILES FOR INITIAL PUBLIC OFFERING Cranbury, NJ, May 17, 2006 - Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock.
View HTML
Toggle Summary AMICUS THERAPEUTICS FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR AT2101 FOR GAUCHER DISEASE
Phase I Clinical Trials Expected to Commence in June
View HTML
Toggle Summary AMICUS THERAPEUTICS FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR AT2101 FOR GAUCHER DISEASE
Phase I Clinical Trials Expected to Commence in June
View HTML
Toggle Summary EUROPEAN REGULATORY COMMITTEE RECOMMENDS ORPHAN MEDICINAL PRODUCT DESIGNATION FOR AMICUS THERAPEUTICS' AMIGAL™ FOR FABRY DISEASE
EUROPEAN REGULATORY COMMITTEE RECOMMENDS ORPHAN MEDICINAL PRODUCT DESIGNATION FOR AMICUS THERAPEUTICS' AMIGAL™ FOR FABRY DISEASE Cranbury, NJ, April 11, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the
View HTML
Toggle Summary AMICUS THERAPEUTICS APPOINTS PHARMACEUTICAL VETERAN DONALD HAYDEN, JR. EXECUTIVE CHAIRMAN OF ITS BOARD OF DIRECTORS
AMICUS THERAPEUTICS APPOINTS PHARMACEUTICAL VETERAN DONALD HAYDEN, JR. EXECUTIVE CHAIRMAN OF ITS BOARD OF DIRECTORS Cranbury, NJ, March 31, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human
View HTML